P. Forde, Kellie N. Smith, J. Chaft, M. Hellmann, T. Merghoub, J. Wolchok, Stephen C. Yang, R. Battafarano, E. Gabrielson, C. Georgiades, G. Rosner, V. Anagnostou, V. Velculescu, S. Topalian, D. Pardoll, J. Brahmer
{"title":"Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.","authors":"P. Forde, Kellie N. Smith, J. Chaft, M. Hellmann, T. Merghoub, J. Wolchok, Stephen C. Yang, R. Battafarano, E. Gabrielson, C. Georgiades, G. Rosner, V. Anagnostou, V. Velculescu, S. Topalian, D. Pardoll, J. Brahmer","doi":"10.1200/JCO.2016.34.15_SUPPL.E20005","DOIUrl":null,"url":null,"abstract":"e20005Background: Nivolumab is an anti-PD1 immune checkpoint blocker which has demonstrated durable responses and improved survival vs. second-line chemotherapy in metastatic non-small-cell lung ca...","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"34 1","pages":""},"PeriodicalIF":42.1000,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.2016.34.15_SUPPL.E20005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 13
Abstract
e20005Background: Nivolumab is an anti-PD1 immune checkpoint blocker which has demonstrated durable responses and improved survival vs. second-line chemotherapy in metastatic non-small-cell lung ca...
期刊介绍:
The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.